News

Wed, 2014-07-23
Dyax Corp. Announces Publication of Scientific Data for DX-2930 in Peer-Reviewed Journals

Dyax Corp. today announced the online publication of scientific data for DX-2930, an investigational fully human monoclonal antibody inhibitor of plasma kallikrein (pKal), in two peer-reviewed journals.

Dyax, a biopharmaceutical company focused on HAE and other plasma-kallikrein-mediated disorders, is developing DX-2930 as a subcutaneous injection for prevention of HAE attacks.

Wed, 2014-07-23
Recommended combination of Shire and AbbVie

The Boards of AbbVie and Shire are pleased to announce that they have reached agreement on the terms of a recommended combination of Shire with AbbVie.

The Transaction will create a well-positioned and focused specialty biopharmaceutical company, with sustainable leadership positions within areas of unmet need, including immunology, rare diseases, neuroscience, metabolic diseases and liver disease (HCV) and multiple emerging oncology programs.

Fri, 2014-07-18
First Subcutaneous Treatment Now Available in Canada

Shire Canada Inc. announced today the availability of FIRAZYR® (icatibant injection) in Canada for the treatment of acute attacks of HAE in adults with C1-esterase inhibitor deficiency. It is the first and only subcutaneous, ready-to-use option available to Canadians living with the rare and serious disorder.

Fri, 2014-07-18
Recommended combination of Shire and AbbVie

The Boards of AbbVie and Shire have reached agreement on the terms of a recommended combination of Shire with AbbVie.

The Transaction will create a well-positioned and focused specialty biopharmaceutical company, with sustainable leadership positions within areas of unmet need, including immunology, rare diseases, neuroscience, metabolic diseases and liver disease, and multiple emerging oncology programs.

Thu, 2014-07-17
FDA approves Ruconest for HAE treatment in the USA

Salix Pharmaceuticals, Ltd. and Pharming Group NV has announced that the US Food and Drug Administration (FDA) has approved Ruconest (C1 Esterase Inhibitor [Recombinant]) 50 IU/kg for the treatment of acute angioedema attacks in adult and adolescent patients with HAE.

Teaser 4, 2nd row left, in news section

United We Stand Strong!

HAEi cares about you. We encourage patients to get organized - because "United We Stand Strong".

HAE International - Thumb 7HAE International - Thumb 7Become a National Member Organization (NMO). We are here to help you in founding a National Member Organization. Follow our step-by-step model. It doesn't have to be a difficult task creating the best foundation for patients in your country. Contact us for more information here


HAE International - Thumb 4HAE International - Thumb 4

Starting a National Patient Group (NPG). If you are interested in doing more around HAE - but don't feel that starting a full NMO is the right option here and now. You should maybe consider becoming a contact patient (NPG) for your country. Contact us here

Both NMO's and NPG's enjoy free membership of HAEi. Also we can help you host your country specific website under the global umbrella of HAEi.

Events

Thu, 2014-11-06 09:00 - Mon, 2014-11-10 16:00

ACAAI - 2014 Annual Scientific Meeting

Venue: Georgia World Congress Convention Center, Atlanta, GA, United States of America
Language: English

Plan to join your colleagues at the 71st ACAAI Annual Scientific Meeting in Atlanta, Nov. 6-10. Broaden your expertise, enhance your practice management skills and improve patient care.

For more information please visit: ACAAI Annual Meeting 2014

..continue
Fri, 2014-10-24 13:00 - Sun, 2014-10-26 12:30

International scientific conference on Expanding Boundaries of our HAE Knowledge

Venue: Bethesda Marriott, 5151 Pools Hill Road, Bethesda, MD 20814, USA
Language: English

This first international scientific meeting on HAE, sponsored by National Institutes of Health in conjunction with the US HAEA Angioedema Center at UCSD, will bring together experts in all types of angioedema, as well as clinical medicine to discuss the emerging basic science.

Read more about the conference here

..continue
Wed, 2014-10-15 12:00 - Thu, 2014-10-16 13:00

Bradykinin Symposium

Venue: Kaiserin Friedrich-Haus, Lecture Hall, Robert-Koch-Platz 7, 10115 Berlin, Germany
Language: English

Welcome to this year's Bradykinin Symposium hosted by the Charité and icare on 15-16 October 2014 in Berlin. International experts in the field of bradykinin have been invited to discuss the role of bradykinin in present and in the future.

The symposium will be complemented by the Charité/UNEV/icare/GA²LEN Angioedema School on 16-17 October 2014.

For more information please visit: Bradykinin Symposium 2014

..continue

Homepage Teaser 6, 2nd row right

HAE Global Community

Be part of the HAEi Community

HAEi is here to help you. Therefore we have created the HAEi Community that gives you all the bells and whistles you know from other social media (such as Facebook) and even a very sophisticated Forum, where you can discuss with fellow HAE patients and care givers. The only difference is - that here your information stays safe - and will only be shared with other HAE patients and care givers. If you are a HAE patient or directly related to a HAE patient we urge you to register today - and become an important member of our community

Help yourself and stay updated by registering already today - then you will be the first to know.....

Do you have Questions?
You can find answers on our FAQ-Page or
send us an e-mail to: info@haei.org
or go to the contact form page


Experiencing browser problems?

Our website is working properly on most web browsers. However, we know that the site will not perform correctly on Microsoft Internet Explorer version 6 and earlier! So if you are using Internet Explorer from Microsoft please ensure that you have version 7 or higher!


See the video from the 2012 HAE Global Conference in Copenhagen

Click here


HAEDAYHAEDAYLook out for next hae day :-) on 16 May 2014


www.haeday.org